Longboard Pharmaceuticals - LBPH EV/EBITDA Multiple
The share price history of Longboard Pharmaceuticals (LBPH) demonstrates EV/EBITDA dynamics, which currently stand at . Longboard Pharmaceuticals manages global supplies of critical neuromolecules, utilizing a network of specialized warehouses to protect research. The business generates revenue from therapies for severe forms of epilepsy, which provide a steady cash flow. Despite the reliance on a single drug, high liquidity and successful test results offset the risks of a narrow portfolio.
Metric breakdowns and analytics for longboardpharma.com (LBPH)
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- debt and liquidity details:
Total Debt to Capital Longboard Pharmaceuticals|LBPH - Long-Term Debt to Capital|Short-Term Debt to Equity Longboard Pharmaceuticals, Inc.|LBPH - Aggregate Debt Obligations|Debts to Book Capitalization Longboard|LBPH - Company Long-Term Indebtedness|Company Current Liabilities Longboard Pharmaceuticals|Quick Liquidity longboardpharma.com
- financial results and valuation multiples details:
LBPH - Profit After Tax|Projected Future Earnings Longboard Pharmaceuticals|LBPH - Company Value to Net Income|Forward P/E Multiple Longboard Pharmaceuticals|LBPH - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard|LBPH - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Longboard Pharmaceuticals|LBPH - Net earnings per share for the last 12 months|Quarterly EPS earnings growth longboardpharma.com|LBPH - Earnings growth in current year|Earnings growth forecast for next year Longboard Pharmaceuticals
Summary company analysis:Longboard Pharma LBPH
For Longboard Pharmaceuticals (LBPH), which develops high-cost therapies for rare epilepsies, the Enterprise Value to EBITDA ratio reflects the market valuation of the business inclusive of all debt obligations. This indicator compares the company's total capital with its operating profit before depreciation, taxes, and interest. The trend of this ratio allows for an assessment of the financial model's stability amidst high innovation costs and asset impairment risks.
Competitor analysis for Longboard Pharmaceuticals
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|NBIX: Enterprise Value to Operating Income Before Depreciation|Regencell Bioscience - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple axsome.com (AXSM)|ACAD: EV/EBITDA Multiple|XENE (Xenon Pharmaceuticals Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Company Value to EBITDA Supernus Corp SUPN|EV/EBITDA Multiple CPRX|EV/EBITDA Multiple denalitherapeutics.com (DNLI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|Business Value to Operating Income Before Depreciation BHVN|Amylyx - EV/EBITDA Multiple|TRVI (Trevi Corp) - Enterprise Value to Operating Income Before Depreciation|PRAX (Praxis Precision Medicines) - Enterprise Value to EBITDA Ratio|anavex.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell|Prothena Corporation PLC - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ALEC|ANNX (Annexon Biosciences Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple OMER (Omeros)|EV/EBITDA Multiple neurogene.com NGNE|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VYGR (Voyager Therapeutics Inc)|Neumora Therapeutics Inc (NMRA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Scilex Holding Company, Inc.|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|EV/EBITDA Multiple Alpha Cognition Corp|EV/EBITDA Multiple CGTX|Enterprise Value to EBITDA Ratio Inhibikase Therapeutics Inc IKT|EV/EBITDA Multiple SAVA (Cassava)|Assertio Holdings (ASRT) - Company Value to EBITDA|COYA: Enterprise Value to EBITDA Ratio|VTGN - EV/EBITDA Multiple|OVID (ovidrx.com) - Enterprise Value to EBITDA Ratio|ABOS: Enterprise Value to Operating Income Before Depreciation Ratio|CRVO (CervoMed Inc) - EV/EBITDA Multiple|Alterity Therapeutics Ltd (ATHE) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CLNN|Enterprise Value to EBITDA Ratio pepgen.com PEPG|EV/EBITDA Multiple JUNS (Jupiter Neurosciences)|EV/EBITDA Multiple Relmada Therapeutics Inc RLMD|ANVS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GRCE: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|KLTO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization RVPH|EV/EBITDA Multiple MTVA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NRXS (NeurAxis Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Helius Medical Technologies HSDT|PASG (Passage Bio Inc.) - Company Value to Operating Income Before Depreciation Ratio|Neuphoria - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation NERV (Minerva Neurosciences Inc)|Athira (ATHA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ADXN|ALZN (Alzamend Neuro Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Cyclerion CYCN|Enterprise Value to EBITDA Ratio PTIX (Protagenic Therapeutics)|EV/EBITDA Multiple pasitheaclinics.com (KTTA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cortigent CRGT|Business Value to Operating Income Before Depreciation ATXI|BCLI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA caratherapeutics.com|Chromocell Therapeutics Corp. (CHRO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ELYM (Eliem Therapeutics Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intra-Cellular Therapies Inc.|Company Value to EBITDA Marinus Pharma MRNS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|neurobopharma.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SAGE (Sage Therapeutics)|Enterprise Value to EBITDA Multiple Synaptogenix Inc.|Trevena, Inc - EV/EBITDA Multiple|VIGL: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Anew Medical, Inc. (WENA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA cerevel.com (CERE)
